Monopar Therapeutics Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 2 - Significant Accounting Policies (Tables)

Note 2 - Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2026

Notes Tables

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

September 30, 2026		*Level 1*				*Total*
Assets:
Cash equivalents⁽¹⁾		$	52,486,931			$	52,486,931
Total		$	52,486,931			$	52,486,931

December 31, 2025		*Level 1*				*Total*
Assets:
Cash equivalents⁽¹⁾		$	60,875,969			$	60,875,969
Total		$	60,875,969			$	60,875,969